Moleculin Reports Additional Preliminary Interim Data From AML Clinical Trial

– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations 

– Current median durability of response (mDOR) of CRc's = 6 months and increasing (n=9) 

– In 2nd line subjects (n=10) Annamycin in combination with Cytarabine (AnnAraC) achieved an estimated median overall survival (mOS) of 6 months and increasing plus 5 CR's (50%) and 6 CRc's (60%)

– Recruitment increased to 22 subjects and CRc's in all subjects evaluable for efficacy (n=20) was 45%

– Annamycin continues to demonstrate no cardiotoxicity

– Data presented at European Hematology Association (EHA) 2024 Hybrid Congress and Company KOL Meeting in Madrid